Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004309813 | SCV003972448 | uncertain significance | not specified | 2023-04-12 | criteria provided, single submitter | clinical testing | The c.1331C>T (p.A444V) alteration is located in exon 7 (coding exon 7) of the POLRMT gene. This alteration results from a C to T substitution at nucleotide position 1331, causing the alanine (A) at amino acid position 444 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Clinical Genomics Laboratory, |
RCV004555909 | SCV005045088 | uncertain significance | Combined oxidative phosphorylation deficiency 55 | 2024-04-05 | criteria provided, single submitter | clinical testing | The POLRMT c.1331C>T (p.Ala444Val) variant, to our knowledge, has not been reported in the medical literature. Computational predictors suggest that the variant does not impact POLRMT function. The highest population minor allele frequency in the population database genome aggregation database (v.2.1.1) is 0.036% in the European non-Finnish population. This variant has been reported in the ClinVar database as a germline variant of uncertain significance by one submitter. Due to limited information, and based on ACMG/AMP guidelines for variant interpretation (Richards S et al., PMID: 25741868), the clinical significance of this variant is uncertain at this time. |